Compare SM Energy Company Common Stock (SM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SM Energy Company Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? SM Energy Company Common Stock trades at $38.17 (market cap $9.17B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: SM Energy Company Common Stock is the larger of the two by market cap, and SM Energy Company Common Stock pays a 2.28% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold SM Energy Company Common Stock for 2 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SM | TVTX | |
|---|---|---|
Market Cap | $9.17B | $4.88B |
Volume | 2,026,791 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $41.29 | $67.52 |
52-Week Low | $17.57 | $26.79 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $15.58B | $5.01B |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SM Energy (SM) trades at $38.54, up 2.26% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with a low P/E of 6.83, healthy profit margins above 19%, and positive cash flow generation. Recent analyst coverage remains overwhelmingly positive with 65% buy ratings and a $39.08 consensus target, slightly above current levels.
Outlook remains favorable given strong earnings momentum and attractive valuation metrics, though overbought RSI readings suggest near-term consolidation risk. The company's upcoming Q3 2026 earnings report on November 3rd represents the next key catalyst for price movement.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SM Energy Company Common Stock
SM Energy is an independent oil and natural gas exploration and production company. Its operations include the Permian, Maverick, Uinta, and Denver-Julesburg basins.
Read more on SM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
